Abstract:Introduction: Escitalopram is an effective and generally well-tolerated antidepressant, but children of parents with bipolar disorder (BD) may be at increased risk for adverse events associated with antidepressants, including increased irritability, restlessness, impulsivity, and manic symptoms. This risk may be influenced by polymorphisms in genes encoding cytochrome P450 enzymes ( CYP2C19 or CYP2D6 ), the serotonin transporter ( SLC6A4 ), and the serotonin receptor 2A subtype ( HTR2A ). We explored whether gene–drug interactions influence the emergence of adverse events in depressed and/or anxious youth with a family history of BD. Materials and Methods: Children and adolescents aged 12–17 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels. Emergence of adverse events was determined by study clinicians, and symptoms were tracked using the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) and Pediatric Adverse Events Rating Scale. Clinical Pharmacogenetics Implementation Consortium guidelines were used to determine CYP2C19 and CYP2D6 phenotypes. Results: Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC 0–24 ; p = 0.025), trough concentrations (C trough ; p = 0.013), and elimination half-lives (t 1/2 ; p < 0.001). CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter. Slower CYP2D6 metabolizers had increased TEASAP akathisia ( p = 0.015) scores. HTR2A A/A and A/G genotypes were associated with increased TEASAP "self-injury, suicidality, and harm to others" subscale scores ( p = 0.017). Escitalopram maximum concentration, AUC 0–24 , CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events. Conclusions: CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not. Slower CYP2D6 metabolism was associated with increased akathisia, and HTR2A A/A or A/G genotypes were associated with increased risk of self-harm or harm to others. Larger cohorts are needed to identify associations between genetic test results and antidepressant-associated adverse events. Trial Registration: ClinicalTrials.gov identifier: NCT02553161.

Buspirone for the treatment of anxiety in Williams syndrome: a retrospective chart review study

Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series

Adaptive Behavior in Chinese Children with Williams Syndrome

Levodopa-responsive dystonia, parkinsonism, and treatment-resistant schizoaffective disorder in Williams syndrome

Depression and Anxiety in Pediatric Patients with Beckwith–Wiedemann Syndrome: A Pilot Study

Behaviour and Psychopathology in Preschool Children with William Syndrome and the Effects of Age, Sex and Cognition

Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study

Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trial

Lack of Deleterious Effects of Buspirone on Cognition in Healthy Male Volunteers

Child/Adolescent Anxiety Multimodal Study: Evaluating Safety

A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder

Sleep-Related Problems and the Effects of Anxiety Treatment in Children and Adolescents

Alleviating anxiety while breastfeeding: evaluating buspirone transfer into human milk

A randomized double-blind placebo-controlled clinical trial of Guanfacine Extended Release for aggression and self-injurious behavior associated with Prader-Willi Syndrome

Glucose and lipid metabolism, bone density, and body composition in individuals with Williams syndrome

Contrasting neurofunctional correlates of face- and visuospatial-processing in children and adolescents with Williams syndrome: convergent results from four fMRI paradigms

Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients

Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study

A profile of mental health and behaviour in Prader-Willi syndrome

010 The prevalence of anxiety in patients with psoriasis: A systematic review of observational studies and clinical trials

Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorder